Trump’s Drug Czar Pick Exposed For Being on Big Pharma’s Payroll

Monday, April 17, 2017
By Paul Martin

By Annabelle Bamforth
April 17, 2017

President Donald Trump’s reported choice to serve as Director of the Office of National Drug Control Policy has raised alarm concerning conflict of interest, as his top pick has been criticized for protecting and benefiting from the pharmaceutical industry.

The ONDCP is responsible for most of the shaping of U.S. drug policy and will also be “providing administrative support” for Trump’s newly-created special commission to combat the opiate crisis. Trump’s top choice, Pennsylvania Congressman Tom Marino, is expected to resign from Congress to become the country’s “drug czar.”

For those who seek to genuinely hold the pharmaceutical industry accountable for its role in the country’s opiate crisis, Marino is a perilous choice. The International Business Times has uncovered troubling background of Marino’s relationship with the pharmaceutical industry, particularly regarding donations.

According to IBT, Marino “would come to the job after pulling in big money from an industry that is producing and distributing the nation’s most deadly legal drugs. Marino has received more than $150,000 in donations from the pharmaceutical industry in his political career, including $71,000 for the 2016 election, according to records at and The data show Marino has received more money from the pharmaceutical industry than any other sector.”

The Rest…HERE

Leave a Reply

Join the revolution in 2018. Revolution Radio is 100% volunteer ran. Any contributions are greatly appreciated. God bless!

Follow us on Twitter